Risk factors of recurrence after radical prostatectomy for locally advanced prostate cancer - Abstract

PURPOSE: We reviewed our retrospective surgical database and assessed the outcome after radical prostatectomy (RP) in patients with clinical T3 (cT3) prostate cancer (PC).

MATERIAL AND METHODS: Sixty four men underwent RP for cT3 PC in our hospital from 1995 to 2011. Clinical stage was diagnosed with MRI and rectal digital examination in all cases. We investigated the postoperative outcome, cancer specific survival and overall survival of all patients. We also investigated the risk factors of biochemical recurrence (BCR) in the patients without any adjuvant therapy. All survival was estimated using Kaplan-Meier plots. We performed univariate analysis by Mann-Whitney test, Fisher exact test and Log-Rank test, and multivariate analysis by Cox regression analysis.

RESULTS: Median age at RP was 67 years (range: 48-74), and median initial PSA was 14.1 ng/ml (2.2-76.2). Sixty cases (93.8%) were classified into cT3a, and 4 cases (6.3%) into cT3b. Median follow-up period after RP was 62 months (3-172). Fifty three (83%) patients received neoadjuvant hormonal therapy. Median duration of neoadjuvant hormonal therapy was 7 months (3-31). Adjuvant therapy underwent in 20 cases. Of the 64 patients, overall survival and cancer specific survival rates at 10 years were 98% and 100%, respectively. Of the 44 patients who didn't receive any adjuvant therapy, BCR free survival rates at 5 and 10 years was 59% and 51%, respectively. Univariate analysis revealed that both PSA > or = 15 ng/ml and GS > or = 8 were associated with a significant risk of BCR. Any significant risk factor was not identified by multivariate analysis. In 16 patients who have cT3a, PSA < 15 ng/ml and GS < 8, BCR free survival rate at 5 years was 78%. On the other hand, that of the other patients was 37% (p = 0.009).

CONCLUSIONS: It is suggested that RP is effective for some patients with locally advanced prostate cancer, especially who have cT3a diagnosed by MRI, PSA < 15 ng/ml and GS < 8.

Written by:
Yamamoto Y, Nakayama M, Ueda N, Takeda K, Nakata W, Kakimoto K, Nishimura K.   Are you the author?

Reference: Nihon Hinyokika Gakkai Zasshi. 2014 Jul;105(3):91-6.

PubMed Abstract
PMID: 25158550

Article in Japanese.

UroToday.com Prostate Cancer Section